Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for RLYB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 5.50M
March 31, 2026 17.90M
December 31, 2025 3.925M
September 30, 2025 29.23M
June 30, 2025 3.035M
March 31, 2025 11.08M
December 31, 2024 -1.573M
September 30, 2024 22.20M
June 30, 2024 2.596M
March 31, 2024 10.26M
December 31, 2023 16.91M
September 30, 2023 3.07M
June 30, 2023 6.214M
Date Value
March 31, 2023 1.465M
December 31, 2022 -30.65M
September 30, 2022 5.772M
June 30, 2022 -7.118M
March 31, 2022 -80.18M
December 31, 2021 -0.137M
September 30, 2021 -0.13M
June 30, 2021 -1.504M
March 31, 2021 -0.562M
December 31, 2020 -0.456M
September 30, 2020 -0.023M
June 30, 2020 -1.001M
March 31, 2020 -0.592M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Q32 Bio, Inc. 0.00
Beam Therapeutics, Inc. -9.875M
C4 Therapeutics, Inc. -14.82M
Cullinan Therapeutics, Inc. 40.68M
Arrowhead Pharmaceuticals, Inc. 43.68M